PROSTATIC NEOPLASMS

This study tests a new type of focused radiation (SBRT) to treat early-stage prostate cancer that hasn't spread. The goal is to destroy only the tumor, not the whole prostate, which may reduce side effects like incontinence and impotence. About 42 men will receive two painless ra…

This study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard drugs (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that worsened after one prior hormone treatment. The goal is to see i…

This study tests a new drug called 177Lu-rhPSMA-10.1 in men with metastatic castrate-resistant prostate cancer, a type of prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells. The study has two phases: Pha…

This study tests a new drug called pocenbrodib, either alone or with other treatments, in people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to find the safest dose and see if it can shrink tumors or lower PSA levels. A…

This early-phase study tests whether combining two experimental antibodies (JNJ-87189401 and JNJ-78278343) can help control advanced prostate cancer that has spread or is no longer responding to standard treatments. About 355 men with advanced prostate cancer will take part. The …

This study tests a new medicine called ifinatamab deruxtecan (I-DXd) against standard chemotherapy (docetaxel) in people with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. The goal is …

This early-stage study tests a new combination of two experimental drugs for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The first drug helps the immune system target cancer cells, while the second delivers a toxin directly to them…

This early-phase study tests a new combination of two drugs for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The first drug helps the body's immune cells attack cancer cells, while the second aims to boost that attack. About 40 part…

This early-phase study tests a new drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; second, giv…

This study looks at whether adding a special PET/CT scan (rhPSMA-7.3) to the usual MRI can find more aggressive prostate cancers in men who are currently just watching their low-risk cancer. About 120 men will get both scans before a confirmatory biopsy. The goal is to see if the…

This study tests a new type of PET scan using a radioactive tracer called 64Cu-SAR-bisPSMA to see if it can better detect prostate cancer that has spread to nearby lymph nodes. About 383 men with high-risk prostate cancer who are scheduled for prostate removal surgery will get th…

This study tests a new radiation technique called adaptive radiotherapy for prostate cancer. It adjusts the radiation beam each day to match changes in the body, which may allow doctors to use smaller treatment margins and reduce side effects. The study has two phases: first, to …

This study looks at whether a low to moderate load power training program can improve quality of life and physical fitness in men with metastatic prostate cancer who are on hormone therapy. About 66 men will either join a supervised exercise program twice a week for 6 months or c…

This study tests whether acupuncture can reduce hot flashes and improve sleep and quality of life in men receiving hormone therapy for prostate cancer. Twenty-four men will be randomly assigned to start acupuncture right away or after a delay, and all will receive standard lifest…

This study follows 500 men aged 30–75 who have specific genetic changes that raise their risk for prostate cancer, but who do not yet have the disease. Researchers will track their health over time using yearly checkups, blood tests, and MRI scans every two years. The goal is to …

This study collects blood samples from 1000 men with prostate cancer to look for genetic differences that may explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. The goal is…

This study reviews medical records of 1,400 men with metastatic hormone-sensitive prostate cancer (mHSPC) to see how darolutamide is used in everyday urology clinics. It compares two treatment approaches: darolutamide plus hormone therapy alone (doublet) or with chemotherapy (tri…

This study watches how closely men with advanced prostate cancer follow their prescribed apalutamide treatment over one year. Researchers will track medication adherence and look for patterns that might predict who struggles to stay on track. The goal is to understand real-world …

This study is for men with prostate cancer who are about to have radiation therapy or whose cancer has come back after earlier treatments. Researchers will use detailed MRI scans and biopsies to see how the tumor responds to radiation and why some cancers return. The goal is to b…

This study follows 3,000 men with low-risk prostate cancer who chose active surveillance (close monitoring instead of immediate treatment). Researchers collect blood, urine, and tissue samples over time to find markers that can tell aggressive cancers from slow-growing ones. The …

This study follows 400 people who have urologic cancer surgery with lymph node removal to see how often leg swelling (lymphedema) happens. Researchers use questionnaires and special devices to measure swelling and tissue fluid over two years. The goal is to better understand this…